Well Referenced

Tag: cardiovascular risks

First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease

A review published in Prescrire International (2013) evaluated first-line treatments for metastatic prostate cancer, focusing on androgen suppression therapies like orchiectomy and gonadorelin agonists, which provide significant pain relief for about 80% of patients with bone metastases. However, the effect of these therapies on overall survival remains uncertain. Nonsteroidal antiandrogen

Read More »
June 26, 2025 No Comments

Overt and subclinical hypothyroidism: who to treat and how

The article “Overt and subclinical hypothyroidism: who to treat and how” discusses the treatment strategies for overt and subclinical hypothyroidism, emphasizing that all patients with overt hypothyroidism and those with subclinical hypothyroidism with thyroid-stimulating hormone (TSH) levels exceeding 10 mIU/L should receive treatment. It highlights the importance of treating pregnant

Read More »
June 26, 2025 No Comments

Hormone replacement therapy and cardiovascular disease revisited

This article revisits the effects of hormone replacement therapy (HRT) on cardiovascular disease, particularly in postmenopausal women. It highlights the Women’s Health Initiative (WHI) study, which initially showed risks such as increased cardiovascular events and cancer, leading to the conclusion that HRT should be avoided. However, further analysis indicated no

Read More »
June 26, 2025 No Comments